Safety and immunogenicity of candidate vaccine M72/AS01E in adolescents in a TB endemic setting
Posted at 17:56h in
Hennie Geldenhuys
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
You can adjust all of your cookie settings by navigating the tabs on the left hand side. You may also review our privacy and cookie policies by visiting our Privacy and Data Protection Page.